Sample Size Based on Pharmacodynamic endpoints [Power / Sample Size]

posted by sury – India, 2019-04-05 06:36  – Posting: # 20122
Views: 1,295

Thanks for your reply.....but i have few more doubts on this

Can we use the pharmacokinetic parameter ISCV for the sample size estimation for the clinical endpoint bioequivalence study?
is it will be in accordance with the regulatory requirement?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

Activity
 Admin contact
20,260 posts in 4,265 threads, 1,401 registered users;
online 34 (0 registered, 34 guests [including 13 identified bots]).
Forum time (Europe/Vienna): 16:26 CET

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5